SHANGHAI – Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX:1672) announces today that the clinical trial application of ASC42 to treat patients with primary biliary cholangitis (PBC) has been accepted for review by China National Medical Products Administration (NMPA). ASC42 is an in-house developed, novel...
Latest News
SHANGHAI, China — Gannex Pharma Co., Ltd. a wholly-owned company of Ascletis Pharma Inc., announces today positive interim results from the 52-week Phase II clinical trial of thyroid hormone receptor β (THRβ) agonist ASC41 tablet for treatment of patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH). ASC41 is liver-targeting and highly THRβ-selective. Once-daily...
SHANGHAI — Gannex Pharma Co., Ltd. (“Gannex”), a wholly-owned company of Ascletis Pharma Inc. (HKEX:1672) announces today that the safety, pharmacokinetics (PK), and pharmacodynamics (PD) data of ASC42, a novel farnesoid X receptor (FXR) agonist, in healthy subjects have been published on the journal Drugs in R&D. In-house developed by...
In an effort to raise funds to pay for a lung transplant needed by Lodi resident Alicia Brogle, the Brogle family will hold a yard sale Friday through Sunday at 729 Westwood Ave. in Lodi. Brogle, 32, lives with cystic fibrosis and needs to use an oxygen machine to breath...
TARRYTOWN, N.Y. — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for garetosmab for the treatment of adults with fibrodysplasia ossificans progressiva (FOP). Garetosmab is a monoclonal antibody that blocks Activin A, a protein that Regeneron scientists discovered to be critical in...
Sydney, Australia – Researchers have discovered how the mechanical properties of tumours can prime cancer cells to better survive their spread to other organs. A metabolic ‘survival switch’ controlled by the stiffness of triple-negative breast tumours can significantly influence how successfully their cancerous cells spread to other organs, according to...
New Haven, CT – Gaucher disease treatment has come a long way in the past three decades. The United States Food and Drug Administration (FDA) approved the first enzyme replacement therapy (ERT) in 1991. That first approval opened the door for other ERT treatments and paved the road for substrate...
SYDNEY – Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an oncology-focused drug development company, is pleased to inform stakeholders that the GBM AGILE study in glioblastoma (NCT03970447) has opened at Sunnybrook Health Sciences Centre in Toronto, Ontario. This marks the first Canadian site to open to paxalisib, and the first...
YONGIN, South Korea — GC Biopharma (006280. KS) and Novel Pharma have announced that the U.S. FDA has cleared the investigational new drug (IND) application for their jointly developed MPSIIIA (Sanfilippo Syndrome Type A) treatment, GC1130A. With this FDA clearance, the development of GC1130A is set to accelerate, with multinational...
YOGIN, South Korea — GC Biopharma Corp today announces that the US Food and Drug Administration (FDA) has approved ALYGLO (immune globulin intravenous, human-stwk) 10% Liquid, formerly referred to as “GC5107,” for the treatment of adult patients aged 17 years and older with primary humoral immunodeficiency (PI). The ALYGLO pivotal...